Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DGH83L
|
|||
| Drug Name |
DNL747
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Amyotrophic lateral sclerosis [ICD-11: 8B60.0; ICD-9: 335.2] | Phase 1 | [2] | ||
| Company |
Denali Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Receptor-interacting protein 1 (RIPK1) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03757325) Study to Evaluate DNL747 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03757351) Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health. | |||
| REF 3 | Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.